In time, some of the CBD industry’s biggest consumers might not even be human!
Pet products are gaining traction and are becoming a lucrative market as people increasingly splurge on their fur babies. Brightfield Group, a cannabis-focused research firm, saw sales of CBD pet products quadruple from about $8 million in 2017 to $32 million in 2022.
By the end of 2026, Brightfield expects the pet cannabis market will reach $1.16 billion in the U.S. alone and businesses are ferociously sniffing out opportunities in the market.
During the 2022 New York Vet Show in New York, New York, Andrew Rosenberg, DVM, DACVD, practice owner of Animal Dermatology & Allergy Specialists, started his exposition on “Cannabidiol (CBD) use for allergic skin disease” by emphasizing the difference between CBD and marijuana and what it meant for CBD to be a supplement.
In identifying to what extent CBD/CBDA helped the study subject, the dogs included in the study had to have a CADESI-4 (Canine Atopic Dermatitis Extent and Severity Index) score of ≥ 10 or < 60 and a pVAS (Pruritic Visual Analog Scale) ≥ 3 cm and < than 8 cm, both scores indicative of the severity of atopic lesions and itch level of the subject.
Dr. Rosenberg reported that there was a significant difference in the pruritic scale from the baseline at week 2 up until the beginning of week 4. On average during week 2, dogs belonging from the treatment group exhibited a 1.9 improvement in the pVAS scale. Furthermore, from week 0 to week 4, there was a 2.2 cm improvement. This meant that there was a difference between the treatment group and placebo group when it comes to how itchy the pets were. Furthermore, it is worth noting that 10 dog owners out of 17 from the treatment group disclosed that there was an effective improvement on itch, and that 10 out of 17 recommend using it again.
Research indicates CBD can improve pruritis condition in some dogs with no severe adverse effects, given appropriate dosage under veterinary care.